Chris Scotto DiVetta

[Eric Lefkofsky @lefkofsky]

Congratulations to @moderna_tx and @Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care.

We are proud to partner with Moderna in support of this important program, and we’re excited to see this work continue to advance for patients.

https://t.co/MVFakPblaU

[Noah Zimmerman @_noahzim_]

The result is Downstrike, a live lightning map with real physics: thunder rings expand at the actual speed of sound.

https://t.co/KoKygMfTtR

[Tempus @TempusAI]

When faced with a complex diagnosis, Artie and his wife Annie sought answers to guide his cancer journey.

Through Tempus xF non-invasive liquid biopsy results, Artie's oncologist, Alan Tan, MD, was able to identify two significant mutations which opened the door to targeted treatment options tailored specifically to his profile.

Watch is full story: https://t.co/nPumsMYrLd

[Eric Topol @EricTopol]

Our understanding for how our brain ages and why our memory slips after age 50 have been completely revamped through 2 new landmark studies of the microglia, the brain immune cells

[Tempus @TempusAI]

Results published in @NaturePortfolio demonstrate that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, demonstrates best-in-class performance across a wide variety of diagnostic and prognostic applications.

By combining large vision models built from pathology images with large language models, PRISM2 unlocks diagnostic-grade precision in research involving cancer detection, biomarker identification and prognosis prediction.

PRISM2 is the largest model trained on the most comprehensive dataset to date, with nearly 700,000 specimens and clinical reports, covering over 2.3 million slides and 14 million question−answer pairs.

Learn more: https://t.co/L7TJTnNd28

[Eric Lefkofsky @lefkofsky]

Q2 was another exceptional quarter for us. Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.

[Shay Boloor @StockSavvyShay]

$TEM Q2 EARNINGS

• Revenue $383M vs Est. $380M
• EPS ($0.04) vs Est. ($0.15)
• EBITDA $8M vs Est. $9M
• Diagnostics Revenue: $289M (+20% YoY)

FY26 Guidance
• Revenue $1.61B vs Est. $1.59B
• EBITDA $65M vs Est. $65M

Tempus says its Personalis partnership has already proven the value of combining “highly sensitive MRD technology” with its commercial infrastructure.

[Tempus @TempusAI]

Today, we reported our second quarter 2026 financial results.

Find details here: https://t.co/lCx5dRlAag

[Tempus @TempusAI]

The latest episode of the @Cardiac_Wire Show takes a deep dive into the #ALERT trial, the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system.

By leveraging the Tempus Next platform, the trial enabled real-time detection of significant disease and automatically delivered notifications with site-specific guideline-based care notifications directly to providers.

Tune in to learn more: https://t.co/8Nrnn7jfWo

[Tempus @TempusAI]

Last chance to register for tomorrow's webinar discussing how #germline results can directly influence personalized treatment selection, surgical decisions, and other aspects of care.

https://t.co/VsQnsbJOne

[Eric Lefkofsky @lefkofsky]

When we started Tempus, the vision was clear: use data and AI to fundamentally change how we treat cancer.

Today, we took a giant step forward by acquiring @PersonalisInc. Integrating their #MRD capabilities directly into the Tempus platform will allow us to better support patients across their entire journey, from initial diagnosis and treatment selection to long-term monitoring and early recurrence detection.

I look forward to what our teams can accomplish together in this next chapter. https://t.co/cXAppCdbQT

[Tempus @TempusAI]

Tempus and @bmsnews leaders recently discussed a real-world, advanced non-small cell lung cancer (#aNSCLC) case study.

By deploying the Tempus Next Pathways platform across 13 community-based health systems, we were able to unlocke a unified, longitudinal view of the patient journey. This drove an 8% lift in guideline-directed biomarker testing.

A recording of the webinar is available for viewing here: https://t.co/p0hvcNvFac

[Tempus @TempusAI]

In an upcoming webinar, Kate Sasser, PhD, Chief Scientific Officer, Tempus and Razik Yousfi, SVP & GM, AI Products, Tempus, will discuss how AI-driven tools are unlocking insights from standard H&E slides to de-risk patient selection and how a holistic, data-driven approach can help design the next generation of successful #ADCs.

Register now: https://t.co/e1ZZUISBlY

[Tempus @TempusAI]

Precision medicine requires data that evolves with patients. By integrating comprehensive molecular profiling with deep clinical data, we are delivering the insights needed to drive more informed, personalized care across the entire cancer continuum.

Discover our solutions: https://t.co/bniaZcSfpJ

[Tempus @TempusAI]

A recording of our #AACR26 Exhibitor Spotlight is now available. Kate Sasser, PhD, Chief Scientific Officer at Tempus, and Neil Bence, PhD, of @bmsnews discuss how #AI and #RWD are shaping the future of oncology drug development.

Access now: https://t.co/hOsT5e0dVE

[Tempus @TempusAI]

“I think that’s a key component of this, and you know we have done some work within our own health system within one EMR, and that’s exciting but really limited. And what Tempus was able to do is they really have created something that can go across multiple EMRs.” – Dr. Melina E. Marmarelis

From an interview published by @ASCO AI in Oncology on the #ASCO26 study, "Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC." The study demonstrated clinically meaningful improvements in biomarker testing rates following the implementation of Tempus Next.

https://t.co/TlikS5RUR6

[Tempus @TempusAI]

Our single, research-ready dataset gives you a complete picture by unifying connected clinical histories,
rich multimodal biology, and a representative patient population.

Assess your cohort’s feasibility with our RWD by submitting your preliminary criteria, and our team will provide a tailored feasibility assessment to help accelerate your research goals: https://t.co/Q6hDRpN9V6

[Tempus @TempusAI]

Together with @YNHH and @MSKCancerCenter, we are pleased to announce the launch of a digital pathology IMS Open-Source Consortium.

Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer.

Read on: https://t.co/uIvTAO321C

[Eric Lefkofsky @lefkofsky]

The tangible benefits of AI - with Preview, we're using models we developed from millions of pathology slides to deliver insights to doctors within 24 hours of sample receipt. This product is game-changing, as it has the potential to fundamentally shift a patient's entire treatment strategy in situations where days matter.

[Tempus @TempusAI]

Thank you to all who joined us today.

The full recording and presentation deck are now available: https://t.co/JV2ipsZnNh #TEMInvestorDay